PriceTargets.com logo

Parabilis Medicines - PBLS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $41.67
  • Forecasted Upside: 0.84%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 1 Strong Buy Ratings
$41.32 As of 08/19/2026 05:00 PM ET
▲ +1.97 (5.01%)

This chart shows the closing price for PBLS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Parabilis Medicines Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PBLS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PBLS

Analyst Price Target is $41.67
▲ +0.84% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Parabilis Medicines in the last 3 months. The average price target is $41.67, with a high forecast of $45.00 and a low forecast of $40.00. The average price target represents a 0.84% upside from the last price of $41.32.

This chart shows the closing price for PBLS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in Parabilis Medicines.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/26/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/24/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/22/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/20/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2026
  • 1 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/20/2026
  • 1 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2026

Latest Recommendations

  • 1 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/7/2026Zacks ResearchUpgradeHold
7/6/2026GuggenheimInitiated CoverageBuy$40.00
7/6/2026Lifesci CapitalUpgradeStrong-Buy
7/6/2026GuggenheimInitiated CoverageBuy$40.00
7/6/2026EvercoreInitiated CoverageOutperform
7/6/2026Bank of AmericaInitiated CoverageBuy$45.00
7/6/2026Leerink PartnersInitiated CoverageOutperform$40.00
(Data available from 8/20/2021 forward)

News Sentiment Rating

0.52 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/22/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/21/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/23/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/22/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2026
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2026
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2026
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2026

Current Sentiment

  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Parabilis Medicines logo
Parabilis Medicines Inc. is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc. is based in CAMBRIDGE, Mass.
Read More

Today's Range

Now: $41.32
Low: $39.07
High: $41.35

50 Day Range

MA: $31.16
Low: $25.01
High: $41.32

52 Week Range

Now: $41.32
Low: $24.51
High: $41.35

Volume

425,079 shs

Average Volume

364,083 shs

Market Capitalization

$4.88 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Parabilis Medicines?

The following sell-side analysts have issued research reports on Parabilis Medicines in the last year: Bank of America Corporation, Evercore Inc, Guggenheim, Leerink Partners, Lifesci Capital, Wall Street Zen, and Zacks Research.
View the latest analyst ratings for PBLS.

What is the current price target for Parabilis Medicines?

0 Wall Street analysts have set twelve-month price targets for Parabilis Medicines in the last year. Their average twelve-month price target is $41.67, suggesting a possible upside of 0.8%. Bank of America Corporation has the highest price target set, predicting PBLS will reach $45.00 in the next twelve months. Guggenheim has the lowest price target set, forecasting a price of $40.00 for Parabilis Medicines in the next year.
View the latest price targets for PBLS.

What is the current consensus analyst rating for Parabilis Medicines?

Parabilis Medicines currently has 1 hold rating, 4 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PBLS will outperform the market and that investors should add to their positions of Parabilis Medicines.
View the latest ratings for PBLS.

What other companies compete with Parabilis Medicines?

Other companies that are similar to Parabilis Medicines include BridgeBio Pharma, Ascendis Pharma A/S, BioMarin Pharmaceutical, Exelixis and Madrigal Pharmaceuticals. Learn More about companies similar to Parabilis Medicines.

How do I contact Parabilis Medicines' investor relations team?

Parabilis Medicines' physical mailing address is 30 ACORN PARK DRIVE 6TH FLOOR, CAMBRIDGE, MA 02140, US. The company's listed phone number is 617-945-9510 and its investor relations email address is [email protected]. The official website for Parabilis Medicines is parabilismed.com. Learn More about contacing Parabilis Medicines investor relations.